Alkermes plc. Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Alkermes plc. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-06-30 was $26.29M, a 1162.22% increase year-over-year.
- Alkermes plc. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-03-31 was $15.71M, a 46.78% decline year-over-year.
- Alkermes plc. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-09-30 was $622.00K, a 88.73% decline year-over-year.
- Alkermes plc. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-06-30 was $2.08M, a 20.10% decline year-over-year.
- Alkermes plc. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2025 was $43.41M, a 57.45% increase from fiscal 2024.
- Alkermes plc. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2024 was $27.57M, a 64.51% increase from fiscal 2023.
- Alkermes plc. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2023 was $16.76M, a 14.62% decline from fiscal 2022.
- Alkermes plc. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2022 was $19.63M, a 22.47% decline from fiscal 2021.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|
| 2026-06-30 | $26.29M 10-Q · filed 2026-07-28 | |
| 2026-03-31 | $15.71M 10-Q · filed 2026-07-28 | |
| 2025-12-31 | $43.41M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $622.00K 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $2.08M 10-Q · filed 2026-07-28 | |
| 2025-03-31 | $29.53M 10-Q · filed 2026-07-28 | |
| 2024-12-31 | $27.57M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $5.52M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $2.61M 10-Q · filed 2025-10-28 | |
| 2024-03-31 | $11.23M 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $16.76M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $3.11M 10-Q · filed 2024-10-24 | |
| 2023-06-30 | $9.13M 10-Q · filed 2024-10-24 | |
| 2023-03-31 | $2.87M 10-Q · filed 2024-10-24 | |
| 2022-12-31 | $19.63M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $858.00K 10-Q · filed 2023-10-25 | |
| 2022-06-30 | $16.20M 10-Q · filed 2023-10-25 | |
| 2022-03-31 | $1.79M 10-Q · filed 2023-10-25 | |
| 2021-12-31 | $25.32M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $4.31M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $18.45M 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $2.05M 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $8.37M 10-K · filed 2023-02-16 | |
| 2020-09-30 | $800.00K 10-Q · filed 2021-10-27 | |
| 2020-06-30 | $3.85M 10-Q · filed 2021-10-27 | |
| 2020-03-31 | $3.07M 10-Q · filed 2021-10-27 | |
| 2019-12-31 | $18.93M 10-K · filed 2022-02-16 | |
| 2019-09-30 | $3.77M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $2.05M 10-Q · filed 2020-10-29 | |
| 2019-03-31 | $10.55M 10-Q · filed 2020-10-29 | |
| 2018-12-31 | $20.88M 10-K · filed 2021-02-11 | |
| 2018-09-30 | $1.32M 10-Q · filed 2019-10-23 | |
| 2018-06-30 | $3.83M 10-Q · filed 2019-10-23 | |
| 2018-03-31 | $13.16M 10-Q · filed 2019-10-23 | |
| 2017-12-31 | $23.52M 10-K · filed 2020-02-13 | |
| 2016-12-31 | $20.31M 10-K · filed 2019-02-15 | |
| 2015-12-31 | $44.97M 10-K · filed 2018-02-16 | |
| 2014-12-31 | $47.58M 10-K · filed 2017-02-17 | |
| 2013-03-31 | $34.36M 10-K · filed 2015-02-24 | |
| 2012-03-31 | $7.81M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $20.86M 10-KT · filed 2014-02-27 |
| 2011-12-31 | $830.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | |
| 2011-03-31 | $5.56M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $6.16M 10-K · filed 2013-05-23 |
| 2010-12-31 | -$756.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | |
| 2010-03-31 | $2.59M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |